Large-scale human myeloma cell line small molecule compound screen dataset

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.

Authors

Institutions

Publication Details

Journal
Scientific Data
Published
2025-04-19
DOI
https://doi.org/10.1038/s41597-025-04989-8
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Large-scale human myeloma cell line small molecule compound screen dataset

Kelli M. Wilson, Craig J. Thomas, Aleksandra M. Michalowski, Xiaohu Zhang et al.
Scientific Data
Multiple Myeloma Research and Treatments
article

Large-scale human myeloma cell line small molecule compound screen dataset

Kelli M. Wilson, Craig J. Thomas, Aleksandra M. Michalowski, Xiaohu Zhang, Beverly A. Mock, V. Keith Hughitt, Zina Itkin, Carleen Klumpp‐Thomas, Crystal McKnight, Sam Michael, Sayeh Gorjifard, Jonathan J. Keats, John K. Simmons, Lu Chen, Paul Shinn
article en

Abstract

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.

Scientific DataVol. 12(1)
Translational Genomics Research Institute (US), University of Washington (US), Natera (United States) (US), National Cancer Institute (US), National Center for Advancing Translational Sciences (US), Center for Cancer Research (US)
Multiple Myeloma Research Foundation, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
Good health and well-being
Openalex Percentile: Top 90%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.